Revolution Medicines at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Revolution Medicines takes part in 1 session at ESMO 2026 in Madrid, and exhibits at Booth 8036. Its program centres on drugs that target RAS-driven cancers. The discussion covers emerging clinical data and next steps for these therapies in non-small cell lung cancer and pancreatic ductal adenocarcinoma.

OrganizationESMO 2026 Attendance
revmed.com
BiotechExhibitor
US oncology company developing RAS(ON) inhibitors, such as daraxonrasib, for RAS-driven cancers including pancreatic and lung cancer.
Booth
Exhibiting at Booth 8036
Satellite
Mon Oct 26
18:30–20:00
Revolution Medicines - Advances in RAS-targeted therapies: emerging clinical data and future directions in NSCLC and PDAC
Sponsored session · with Clínica Universidad de Navarra, Hospital Clínic de Barcelona, Klinik Floridsdorf
Lung & thoracic cancersGastrointestinal cancers

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Revolution Medicines

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction